Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Director departure
|
|
eFFECTOR Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/31/2021 |
8-K
| Director compensation was amended/approved|
Docs:
|
"Amended and Restated Certificate of Incorporation of eFFECTOR Therapeutics, Inc",
"Amended and Restated Bylaws of eFFECTOR Therapeutics, Inc",
"Amended and Restated Registration Rights Agreement, by and among eFFECTOR Therapeutics, Inc., eFFECTOR Therapeutics Operations, Inc., Locust Walk Sponsor, LLC and certain stockholders",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter from WithumSmith+Brown, PC to the Securities and Exchange Commission",
"Unaudited condensed financial information of Old eFFECTOR as of and for the three and six months ended June 30, 2021",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations of Old eFFECTOR" |
|
| 05/27/2021 |
8-K
| Director compensation was amended/approved|
Docs:
|
"United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 May 26, 2021 Date of Report Locust Walk Acquisition Corp. Delaware 001-39866 85-3306396 200 Clarendon Street, 51st Floor, Boston, MA 02116 Registrant's telephone number, including area code: 697-0763 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ☐ Pre-commencement...",
"Agreement and Plan of Merger, by and among Locust Walk Acquisition Corp., Locust Walk Merger Sub, Inc. and eFFECTOR Therapeutics, Inc",
"Sponsor Support Agreement by and among Locust Walk Sponsor, LLC, eFFECTOR Therapeutics, Inc. and Locust Walk Acquisition Corp",
"Sponsor Lock-up Agreement by and between Locust Walk Sponsor, LLC and Locust Walk Acquisition Corp",
"Form of Subscription Agreement",
"Form of Amended and Restated Registration Rights Agreement",
"eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies",
"Investor Presentation",
"Investor Presentation",
"Script for Investor Webcast" |
|
|
|